17 oktobner 2016:
Zie ook deze artikelen:
Enkele voorbeelden van nog veel meer hebben we gekopieerd van de site van Dr. Bihary Maar nogmaals wat voor waarde dit allemaal heeft weten we niet. Een Nederlandse man heeft aan ons zomer 2004 laten weten erg veel profijt te hebben van de injecties met LDN - Low Dose Naltrexone die worden toegediend door een Nederlandse orthomoleculaire arts.
W. is a 69-year-old man with multiple myeloma, diagnosed in the summer of 1998 when a medical workup for severe back pain (that occurred while playing golf ) revealed fractures of three vertebrae. Tumor was present in several other bones, blood counts were low, and a bone marrow biopsy showed 20% replacement of normal marrow with myeloma cells. His serum paraproteins were very high, as they often are in people with myeloma, at 12.6 and with no response to high dose chemotherapy.
He started LDN in January 1999 and continued intermittent chemotherapy until October 1999. Since then, he has had no chemotherapy but remained on LDN daily. There has been a gradual normalization of all of his blood counts, as well as a drop in his abnormal serum proteins from 12.6 to a normal level of 1.4. Bone scans show continued slow healing of affected bones, and two bone marrow biopsies have shown no sign of myeloma. He has deferred plans for a high-dose chemotherapy with stem cell transplant procedure which had been tentatively scheduled for May 2000, and has decided to "watch and wait" while continuing nightly LDN. He is back to playing golf and tennis regularly.
C. is a 50-year-old woman with carcinoid, a malignancy that generally arises in the appendix or small intestine and spreads to the bones and throughout the abdominal cavity. She started LDN in June 1999. At that time, she had considerable abdominal swelling, diarrhea two to three times a day, frequent episodes of flushing due to the tumor, poor energy and appetite, and significant metastatic spread to numerous bones. No other treatment for the cancer was administered; none was available.
By December 1999, much of the cancer-induced swelling of the abdomen had receded, the diarrhea had completely stopped, the flushing had stopped, and the pain in her right elbow, due to a bony metastasis, had markedly decreased. A telephone follow-up call in April 2000 indicated that she was experiencing only minimal symptoms. Follow up in February 2001 indicated that she still had some of the above symptoms and, though clinically stable, was not showing further movement towards remission.
J. is a 9-year-old girl with neuroblastoma, which was diagnosed at age 5. Her parents were advised in April 1999 that her outlook beyond the next several months would be hopeless. By the time she started LDN (at a pediatric dosage) in June 1999, her blood counts were all very low and bone marrow biopsies confirmed significant crowding out of normal bone marrow elements by tumor.
By late November 1999 her blood counts had all returned to normal and bone marrow biopsies showed a 90% reduction in the amount of tumor present. At that time, her family decided to discontinue chemotherapy and just continue on nightly LDN. She continues to do well. Repeat bone scan, bone marrow biopsy and blood counts are all within normal limits except for a small mass in the area of the right adrenal gland.
M. is a patient in his late 50’s who first visited Dr. Bihari in June 2000. A chronic cigarette smoker, he was told in May 2000 that he had metastatic non-small cell lung cancer. Many abnormal opaque areas had been seen on his chest x-ray, and a biopsy performed on a sizable mass in his right neck had confirmed the diagnosis. He had refused chemotherapy. On examination, he had a 3cm x 4cm x 2cm mass in his right neck. He was started on LDN in mid-June 2000 and, at the beginning of November, revisited Dr.Bihari for the first time. At that time, the patient reported that energy was better and his appetite was good. He had regained 15 pounds, and had returned to working full time. The volume of the neck mass appeared to have decreased by 50%. An MRI exam in November 2000 showed 80% shrinkage of the right neck mass and 20% shrinkage of the masses in both lungs.
V., a 49-year-old woman, first visited Dr. Bihari in early September 2000. She had a five-year history of ovarian carcinoma, with a persistently growing tumor despite repeated courses of chemotherapy and multiple debulking surgery. There was recent increased involvement of the descending colon with the disappearance of formed stools, and she was now experiencing vomiting. Hospitalization was under consideration. She had lost 15 pounds in the two weeks prior to her visit.
She was started on LDN at that time, in addition to her existing low-dose Taxol therapy, and within ten days the signs of large bowel obstruction had disappeared. In four weeks, a repeat CA 125 revealed that this tumor marker had dropped from 1600 to 87. Within the first week of November 2000, it was reported down to 42, and her gynecologic oncologist told her that, on abdominal-pelvic examination, he found no masses. She had regained some 25 pounds and felt “wonderful”. A repeat MRI showed no visible masses. In March 2001, the CA 125 had risen to 52, then 70, with no return of symptoms or of palpable masses on abdominal and pelvic exams.
- Naltrexone blijkt een prima middel bij auto-immuunziektes. Zie hier laatste studieresultaten bij o.a. ziekte van Crohn, MS - Multiple Sclerose en uitleg wat LDN - Low Dose Naltrexone precies is.
- Het werkingsmechanisme van Naltrexone
- Onderzoeksgeschiedenis van Naltrexone
- Beschrijving van 242 patienten die naltrexone kregen als aanvullende behandeling.
- Voorbeelden van patiënten die Naltrexone gebruiken.
- LDN - Low Dose Naltrexone is een niet toxisch middel dat voor enkele toepassingen goedgekeurd is door de FDA